Capital One Financial Analysts Reduce Earnings Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Analysts at Capital One Financial reduced their Q2 2024 EPS estimates for Day One Biopharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. Capital One Financial analyst N. Quibria now anticipates that the company will post earnings per share of ($0.77) for the quarter, down from their prior forecast of ($0.71). The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. Capital One Financial also issued estimates for Day One Biopharmaceuticals’ Q3 2024 earnings at ($0.73) EPS, Q4 2024 earnings at ($0.68) EPS, FY2024 earnings at ($2.90) EPS, FY2025 earnings at ($2.47) EPS, FY2026 earnings at ($1.29) EPS, FY2027 earnings at ($0.17) EPS and FY2028 earnings at $0.83 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Other analysts have also issued reports about the stock. HC Wainwright dropped their target price on shares of Day One Biopharmaceuticals from $50.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. The Goldman Sachs Group dropped their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $37.67.

Day One Biopharmaceuticals Price Performance

DAWN opened at $16.41 on Thursday. Day One Biopharmaceuticals has a 1 year low of $9.67 and a 1 year high of $18.07. The stock’s 50 day simple moving average is $15.46 and its 200 day simple moving average is $14.19. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -6.89 and a beta of -1.44.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 7,615 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $116,128.75. Following the sale, the chief executive officer now directly owns 721,813 shares of the company’s stock, valued at $11,007,648.25. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Charles N. York II sold 8,078 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $17.85, for a total value of $144,192.30. Following the transaction, the chief financial officer now owns 217,293 shares in the company, valued at $3,878,680.05. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jeremy Bender sold 7,615 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $116,128.75. Following the sale, the chief executive officer now directly owns 721,813 shares of the company’s stock, valued at approximately $11,007,648.25. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 195,247 shares of company stock worth $3,376,817. 8.40% of the stock is owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Day One Biopharmaceuticals by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock valued at $56,807,000 after purchasing an additional 346,090 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 38.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock valued at $5,486,000 after acquiring an additional 125,050 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Day One Biopharmaceuticals by 22.4% in the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock worth $2,703,000 after acquiring an additional 40,387 shares during the period. TimesSquare Capital Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 41.8% during the third quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock valued at $14,020,000 after purchasing an additional 336,910 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in Day One Biopharmaceuticals by 5.5% during the third quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock valued at $2,173,000 after purchasing an additional 9,219 shares during the period. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.